MAJHARUL ISLAM

Mr. MAJHARUL ISLAM


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
MMMohsina Akter Mou
Mohsina Akter Mou
NKNawshin Atia Keya
Nawshin Atia Keya
MIMAJHARUL ISLAM
MAJHARUL ISLAM
JHJahid Hossain
Jahid Hossain
SHSyeed Al Habib
Syeed Al Habib
Foysal AhammadFoysal Ahammad
Foysal Ahammad
Breast cancer ranked second among most frequent cancer in the world playing a significant role in mortality rate. Having prior knowledge on differentially expressed genes in breast cell carcinoma elucidated important indications to understand the molecular mechanism underneath breast carcinogenesis. In this study we have investigated the distinguished CSN1S1 expression in human breast cancer. We have analyzed CSN1S1 mRNA expression between cancer and normal tissues using TCGA datasets. Moreover, analysis including promoter methylation, mutations, prognosis, co-expression, gene ontology, and pathways of CSN1S1 were performed by the TCGA Wanderer, UCSC Xena, cBioPortal, PrognoScan, UALCAN, and Enricher server. We have observed low mRNA expression and high promoter methylation of CSN1S1 in cancer tissues compared to normal tissues. Furthermore, we have also identified low mRNA expression in clinicopathological patients, as well as 9 deleterious mutations with highly co-expressed protein MRC1, and significantly related signaling pathways. We have found a positive correlation between the lower expression of CSN1S1 and patients surviving with breast cancer. Here we have concluded that CSN1S1 acts as a biomarker for the surveillance and prognosis of breast cancer, and also works as a novel therapeutic target at the molecular and pathway levels.

20 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FNFahim Alam Nobel
Fahim Alam Nobel
MIMAJHARUL ISLAM
MAJHARUL ISLAM
MAMohammad Asaduzzaman
Mohammad Asaduzzaman
SZSaad Al Zamane
Saad Al Zamane
FJFarha Matin Juliana
Farha Matin Juliana
MIMohammod Johirul Islam
Mohammod Johirul Islam
TPX2, a spindle assembly factor encoded by the TPX2 gene, plays a pivotal role in tumor progression and cellular transformation. Overexpression of TPX2 has been widely documented across multiple malignancies, including breast cancer, and is associated with poor clinical outcomes, including increased metastasis, recurrence, and poor prognosis. Functional studies using TPX2-specific siRNA have demonstrated its critical role in cancer cell proliferation, showing that TPX2 knockdown impairs key proteins involved in the G1-to-S phase transition, reduces motility, and limits cellular invasiveness. Moreover, TPX2 depletion has been shown to induce genomic instability in liver cancer cells, resulting in multinucleation and DNA damage, making it a promising therapeutic target in cancer treatment. Bioinformatic tools, including Oncomine, The Cancer Genome Atlas (TCGA), Kaplan-Meier Plotter, and Breast Cancer Gene-Expression Miner, have been employed to elucidate TPX2’s prognostic significance in breast cancer. Additionally, plant-derived secondary metabolites, which contribute to over 60% of anticancer drugs, hold promise as therapeutic agents. However, discovering viable therapeutic compounds through high-throughput screening (HTS) and computer-aided drug design (CADD) remains a challenge. CADD techniques, including pharmacoinformatic, molecular docking, and molecular dynamics (MD) simulations, and MM-PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) have been instrumental in identifying bioactive compounds. Because TPX2 itself lacks a canonical druggable pocket and acts largely through protein–protein interactions, Aurora kinase A (AURKA)—the mitotic kinase that TPX2 activates and stabilizes—was targeted as the druggable effector of the TPX2–AURKA axis. Computational screening of 61 phytochemicals against Aurora kinase A identified three candidates with high binding affinities. Pharmacokinetic evaluations revealed these compounds met Lipinski's Rule of Five, confirming their drug-likeness. In addition, in silico ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling demonstrated favorable toxicity profiles for these compounds, a critical factor in early drug development. This study underscores the potential of integrating computational approaches to identify novel therapeutic agents targeting the TPX2–Aurora A axis, providing a promising strategy for developing treatments for breast cancer and other TPX2-associated malignancies.